18 March 2019

Scandion Oncology Signs Contract with Solural Pharma to Formulate SCO-101 Tablets for Clinical Phase II Trial

Attachments Download report
· Scandion Oncology A/S and Solural Pharma ApS have entered into an agreement regarding manufacturing of SCO-101 tablets for clinical phase II trials with drug-resistant cancer patients.

· Scandion Oncology will soon be completing the validation and substance production of SCO-101 at Cambrex, Sweden. Next step will be to initiate production of tablets. Scandion Oncology has employed an experienced team of drug production specialists. The team has previously been involved in the original production and formulation of SCO-101 in the four completed phase I studies.

· Saniona, the main shareholder in Scandion Oncology, recently performed a legally required audit of Solural Pharma. This audit is valid and usable for Scandion Oncology.

· The manufacturing of SCO-101 tablets is in accordance with Scandion Oncology’s plans and targets for 2019.

CEO of Scandion Oncology, Nils Brünner:

“The preparation of the clinical phase II trial is progressing in accordance with our plans and we are pleased to have entered into an agreement with Solural Pharma. This is a key step in our process to initiate clinical trials in Q4 2019.”

Mr. Brünner continues:

“Scandion Oncology’s QA experienced pharmaceutical and chemical development team has previously collaborated closely with Solural Pharma, who has a strong background in this field. I am therefore very confident that Solural Pharma will manufacture SCO-101 tablets according to our plans and targets for 2019.”

For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO, Scandion Oncology A/S
Phone: +45 26 14 47 08
E-mail: nb@scandiononcology.com

About Scandion Oncology A/S:
Scandion Oncology A/S
is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. It has been shown in in vitro-studies that SCO-101 restores chemotherapy sensitivity in resistant cells. Scandion Oncology was listed on Spotlight, Sweden in November 2018.

About Solural Pharma ApS:

Solural Pharma ApS is a Danish specialty pharma company founded in 2012. Solural Pharma is specialized to offer Pharmaceutical Development support especially in case where challenging physical/chemical properties or when specialized release profiles of potentially more active drug substances demands the need for dedicated technologies.

Attachments Download report